Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche Tecentriq + Avastin met primary endpoint- liver cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jan 19, 2023 2:34pm

179 Views

Post# 35233873

RE:Roche Tecentriq + Avastin met primary endpoint- liver cancer

@Noteable. Thank you for that info.. I remember a recommendation that reolysin should be used as a monotherapy in Africa for liver cancer. I think the recommendation was out of the UK. Anyway I could be wrong.

To digress, the absence of the presentation is curious, and I can only imagine it was taken down at the request of a third party.

Thanks for the many info posts.

Good luck to all.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 1, 2024